KYMR
Kymera Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.07%
vs ±18.2% implied · ×0.00
shaded = implied · ▲▼ = realized
Kymera Therapeutics, Inc.
128.47
No thesis.
Linked news
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $1.4B | 12.63% | +5.55% | |
| 2 | Baker Bros. AdvisorsBaker Bros. | $992.7M | 8.86% | 0.00% | |
| 3 | venBio Select AdvisorvenBio Select Advisor | $857.1M | 7.65% | 0.00% | |
| 4 | T. Rowe Price AssociatesT. Rowe Price | $815.6M | 7.28% | +17.36% | |
| 5 | T. Rowe Price Investment ManagementT. Rowe Price | $717.5M | 6.40% | +14.50% | |
| 6 | BlackRockBlackRockindex-like | $635.1M | 5.67% | +9.43% | |
| 7 | BVFBVF | $444.0M | 3.96% | −29.63% | |
| 8 | Wellington Management GroupWellington | $421.4M | 3.76% | −5.52% | |
| 9 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $343.1M | 3.06% | +4.11% | |
| 10 | SirenSiren | $336.7M | 3.00% | −7.88% | |
| 11 | Vanguard Capital ManagementVanguardindex-like | $336.3M | 3.00% | +1.81% | |
| 12 | Atlas Venture Life Science AdvisorsAtlas Venture Life Science | $326.5M | 2.91% | −37.80% | |
| 13 | State StreetState Streetindex-like | $313.9M | 2.80% | +14.54% | |
| 14 | Geode Capital ManagementGeodeindex-like | $208.3M | 1.86% | +10.39% | |
| 15 | Capital Research Global InvestorsCapital Research Global Investors | $159.3M | 1.42% | −17.00% | |
| 16 | Goldman Sachs GroupGoldman Sachs | $136.2M | 1.21% | +33.65% | |
| 17 | UBS GroupUBS | $115.6M | 1.03% | −1.57% | |
| 18 | AlliancebernsteinAlliancebernstein | $112.6M | 1.00% | +10.53% | |
| 19 | Driehaus Capital ManagementDriehaus | $105.4M | 0.94% | −11.92% | |
| 20 | MerckMerck | $88.5M | 0.79% | 0.00% | |
| 21 | Norges BankNorges Bankindex-like | $86.8M | 0.77% | — | |
| 22 | Federated InvestorsFederated Investors | $85.9M | 0.77% | +39.64% | |
| 23 | Dimensional Fund AdvisorsDimensional | $85.4M | 0.76% | +25.68% | |
| 24 | Frontier Capital ManagementFrontier | $85.0M | 0.76% | −2.50% | |
| 25 | UBS Asset Management AmericasUBS Asset Management Americas | $84.5M | 0.75% | −15.87% |
282 managers report $11.2B of Kymera Therapeutics on form 13F for the quarter ended Jun 30 '26. 21 of them hold 80% of it; FMR is largest at 12.63%.
Expected move
Inputs8Q avg ±2.2%·×18.03·rich
straddle ±43.5%
spot 126.63exp Jan 15ATM strike 125ATM straddle 64.75IV 143%